BioCryst Pharmaceuticals
BCRX
102 hedge funds and large institutions have $555M invested in BioCryst Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 34 increasing their positions, 28 reducing their positions, and 22 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 28
10% more call options, than puts
Call options by funds: $4.45M | Put options by funds: $4.04M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1% less funds holding
Funds holding: 103 → 102 (-1)
5% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 22
18% less capital invested
Capital invested by funds: $677M → $555M (-$122M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$47.4M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$7.39M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.25M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.82M |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$2.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$7.98M |
| 2 |
D.E. Shaw & Co
New York
|
-$4.04M |
| 3 |
Two Sigma Investments
New York
|
-$3.29M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$2.79M |
| 5 |
Morgan Stanley
New York
|
-$2.49M |
BCRX Hedge Fund Activity: Q3 2014 in Review
102 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2014, worth a combined $555M — down 18% from $677M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of BCRX and 21 opened new positions — a net loss of 1 holder — while 28 trimmed existing stakes and 34 added.
The largest buyer was RA Capital Management, adding an estimated $47.4M. The largest seller was Bogle Investment Management, exiting entirely with an estimated $7.98M sold.
- 102 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2014, down from 103 in Q2 2014.
- Funds reported $555M of BioCryst Pharmaceuticals stock for Q3 2014, down 18% quarter-over-quarter.
- 21 funds opened new BioCryst Pharmaceuticals positions in Q3 2014 and 22 closed out, a net change of -1 holder.
- The largest BioCryst Pharmaceuticals buyer in Q3 2014 was RA Capital Management, an estimated $47.4M added.
- The largest BioCryst Pharmaceuticals seller in Q3 2014 was Bogle Investment Management, an estimated $7.98M sold.
Based on aggregated 13F filings for Q3 2014.